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Abstract
IBD is a gastro-intestinal disorder marked with chronic inflammation of intestinal epithelium, dam-
aging mucosal tissue and manifests into several intestinal and extra-intestinal symptoms. Currently used 
medical therapy is able to induce and maintain the patient in remission, however no modifies or reverses 
the underlying pathogenic mechanism. The research of other medical approaches is crucial to the treatment 
of IBD and, for this, it´s important to use animal models to mimic the characteristics of disease in real life. 
The aim of the study is to develop an animal model of TNBS-induced colitis to test new pharmacological ap-
proaches. TNBS was instilled intracolonic single dose as described by Morris et al. It was administered 2,5% 
TNBS in 50% ethanol through a catheter carefully inserted into the colon. Mice were kept in a Tredelenburg 
position to avoid reflux. On day 4 and 7, the animals were sacrificed by cervical dislocation. The induction 
was confirmed based on clinical symptoms/signs, ALP determination and histopathological analysis. At day 4, 
TNBS group presented a decreased body weight and an alteration of intestinal motility characterized by diar-
rhea, severe edema of the anus and moderate morbidity, while in the two control groups weren’t identified 
any alteration on the clinical symptoms/signs with an increase of the body weight. TNBS group presented the 
highest concentrations of ALP comparing with control groups. The histopathology analysis revealed severe 
necrosis of the mucosa with widespread necrosis of the intestinal glands. Severe hemorrhagic and purulent 
exsudates were observed in the submucosa, muscular and serosa. TNBS group presented clinical symptoms/
signs and histopathological features compatible with a correct induction of UC. The peak of manifestations 
became maximal at day 4 after induction. This study allows concluding that it’s possible to develop a TNBS-
induced colitis 4 days after instillation.
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Resumo
DII é um distúrbio gastro-intestinal caracterizado por inflamação crónica do epitélio intestinal com 
dano associado da mucosa, manifestando-se a partir de sintomas intestinais e extra-intestinais. A terapia mé-
dica utilizada é capaz de induzir e manter o doente em remissão, mas não modifica ou inverte o mecanismo 
patogénico subjacente. A procura de outras abordagens terapêuticas é crucial para o tratamento de DII e, 
para tal, é importante o uso de modelos animais para mimetizar as características da doença. O objetivo do 
estudo é desenvolver um modelo animal de colite induzida por TNBS de modo a testar novas abordagens 
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farmacológicas. O TNBS foi instilado por via intracolónica em dose única como descrito por Morris et al. Foi 
administrado 2,5% de TNBS em 50% de etanol através de um cateter inserido no cólon. Os animais foram 
mantidos em posição Tredelenburg para evitar o refluxo. Nos dias 4 e 7, os animais foram sacrificados por 
deslocamento cervical. A indução de colite foi caracterizada com base nos sintomas/sinais clínicos, determi-
nação de ALP e análise histopatológica. No dia 4, o grupo TNBS apresentou uma diminuição do peso corpo-
ral e uma alteração da motilidade intestinal caracterizada por diarreia, edema severo do ânus e morbilidade 
moderada, enquanto nos dois grupos controlo não foram identificados quaisquer alterações nos sintomas/
sinais clínicos com um aumento do peso corporal. O grupo TNBS apresentou as maiores concentrações de 
ALP, comparando com os grupos controlo. A análise histopatológica demonstrou necrose grave da mucosa 
com necrose generalizada das glândulas intestinais. Foi observado exsudato hemorrágico e purulento ao 
nível da submucosa, muscular e serosa. O grupo TNBS apresentou sintomas / sinais clínicos e característi-
cas histopatológicas compatíveis com uma correta indução de colite. O pico das manifestações tornou-se 
máximo ao 4º dia após a indução. Este estudo permite concluir que é possível desenvolver colite induzida 
por TNBS 4 dias após a instilação.
Palavras-chave: DII, Colite induzida por TNBS, Inflamação, Vias metabólicas, Alvos farmacológicos.
Introdution 
Inflammatory bowel diseases (IBD), which in-
clude Crohn’s disease (CD) and ulcerative colitis 
(UC), are chronic inflammatory diseases of the gas-
trointestinal tract, characterized by chronic recur-
rent ulceration of the bowels1. IBD affects between 
7–10% of people worldwide, mainly of Caucasian de-
scent2,3, promoting significant gastrointestinal symp-
toms, like bloody diarrhea, abdominal pain, anemia, 
weight loss and other extra-intestinal manifesta-
tions1. Interplay between several factors, like genetic 
predisposition, environmental trigger and aberrant 
immune reaction seem to contribute to initiation 
and progression of IBD4,5.
Pathogenesis of IBD is not fully understood, 
but two broad hypotheses have arisen regarding its 
fundamental nature. The first contends that primary 
dysregulation of the mucosal immune system leads 
to excessive immunologic responses to normal mi-
croflora. The second suggests that changes in the 
composition of gut microflora and/or deranged epi-
thelial barrier function elicit pathologic responses 
from the normal mucosal immune system. Current-
ly, it’s well accepted that IBD is indeed characterized 
by an abnormal mucosal immune response but that 
microbial factors and epithelial cell abnormalities 
can facilitate this response6.
Currently used medical therapy of IBD consists 
of salicylates, corticosteroids, immunosuppressants 
and immunomodulators. These drug treatments 
aim to induce and maintain the patient in remission 
and ameliorate the disease’s secondary effects, 
rather than modifying or reversing the underlying 
pathogenic mechanism1,7. Second-generation agents 
have been developed with improved drug delivery, 
increased efficacy and decreased side effects 
frequency1. However, their use may result in severe 
side effects and complications, such as an increased 
rate of malignancies or infectious diseases7. The 
research of other medical approaches is crucial to 
the treatment of IBD and, for this, it is important to 
use animal models to mimic the characteristics of 
disease in real life8.
Animal models are widely used to study patho-
genesis of human diseases and to test new thera-
peutics9. Most of these models are based either on 
chemical induction, immune cell transfer or gene 
targeting4. Trinitrobenzene sulfonic acid (TNBS) 
promotes a chemical induction of colitis by intrarec-
tal instillation of the haptenating substances TNBS 
dissolved in ethanol resulting in acute inflammation 
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with ulcers in rat and mouse10. The acute transmural 
damage became maximal from 3 days to 1 week af-
ter instillation, and resolved within 2 weeks8,10-12. The 
protocols of the TNBS-induced IBD model are not 
standardized, such as the dosage of TNBS, the depth 
of TNBS administration, and the time point for mod-
el evaluation. Therefore, it knows that the effects of 
TNBS are dose dependent8. Thus, the aim of the 
study is to develop an animal model of TNBS-induced 
colitis to test new pharmacological approaches.
Material and methods
Materials
TNBS 5% aqueous solution was purchased from 
Sigma Chemical Co. Ketamine (Imalgene® 1000) was 
purchased from Merial. Xilazine (Rompun® 2%) was 
purchased from Bayer. ADVIA® kit was purchased 
from Siemens Healthcare Diagnostics.
Animals
Male CD-1 mice, 30-40 g in weight and 5-6 
weeks of age, were housed in standard polypropyl-
ene cages with ad libitum access to food and water 
in the Faculty of Pharmacy Central Animal Facility in 
the University of Lisbon. 
Experimental groups
Three groups of mice were used in the study, 
which received an intracolonic administration of dif-
ferent preparations. The first group (n = 6) received 
100 µl of 2.5% of TNBS in 50% ethanol (TNBS group) 
for induction of TNBS-colitis. The second group (n 
= 3) received 100µl of 50% ethanol (ethanol group). 
The third group (n = 2) received 100µl of saline so-
lution (sham group). It was used two control ani-
mals groups, namely ethanol and sham group.
Induction of TNBS-colitis
TNBS was instilled intracolonic single dose 
as described by Morris et al (1989). Briefly, mice 
were left unfed during 24h. In the induction day, 
mice were anesthetized with Ketamine 100mg/Kg 
+ Xilazine 10mg/Kg IP and a catheter was carefully 
inserted into the colon until the tip was 4 cm proxi-
mal to the anus. Then, 2,5% TNBS in 50% ethanol 
was administered and mice were kept for 1 min in 
a Tredelenburg position to avoid reflux13,14. On day 
4 and 7, the animals were sacrificed by cervical dis-
location, however a cardiac puncture was made 
immediately before in order to obtain samples 
for determination of serum alkaline phosphatase 
(ALP). The abdomen was opened by a midline 
incision. The small intestine and colon were re-
moved, freed from surrounding tissues and washed 
with phosphate buffered saline. The results be-
tween day 4 and 7 were subsequently compared.
Clinical symptoms/signs
The animals were observed daily, monitoring 
body weight, morbidity, stool consistency and anus 
appearance.
Biochemical Marker
ALP in the sample catalyzes the hydrolysis of 
colorless p-nitrophenyl phosphate to give p-nitro-
phenol and inorganic phosphate. At the pH of the 
assay (10.3 e 10.4), the p-nitrophenol is in the yellow 
phenoxide form. The rate of absorbance increase at 
410/478 nm is directly proportional to the ALP activ-
ity in the sample. Optimized concentrations of zinc 
and magnesium ions are present to activate the ALP 
in the sample. The measurement was made by an 
automatic analyzer: ADVIA 1200.
Histopathological analysis
Histopathology was carried out by an inde-
pendent histopathologist of the Faculty of Veteri-
nary Medicine of Universidade Lusófona de Humani-
dades e Tecnologias. The intestine samples were 
fixed in 10% neutral buffered formalin, processed 
routinely for paraffin embedding, sectioned at 5 
µm, and stained with hematoxylin and eosin. The 
morphological features of small intestine and colon 
were evaluated in the same conditions for all stud-
ied groups (TNBS group, ethanol group and sham 
group), according the number of days after induc-
tion and the localization of sections. It was evalu-
ated at day 4 and 7, with several sections of small 
intestine due to its length and with three sections of 
colon (proximal to the cecum, in the middle of the 
colon and distal to the rectum). 
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Microscopic assessment of colitis severity
The assessment of colitis severity was based on 
previously described parameters15: 
a) epithelial damage (0 = none, 1 = minimal 
loss of goblet cells, 2 = extensive loss of goblet cells, 
3 = minimal loss of crypts and extensive loss of gob-
let cells, and 4 = extensive loss of crypts); 
b) infiltration (0 = none, 1 = infiltrate around 
crypt bases, 2 = infiltrate in muscularis mucosa, 3 = 
extensive infiltrate in muscularis mucosa with ede-
ma, and 4 = infiltration of submucosa). 
The histological activity index (HAI) was calcu-
lated as the sum of the epithelium and infiltration 
score, resulting in the total HAI score ranging from 
0 (unaffected) to 8 (severe colitis).
Results 
Monitoring of clinical symptoms/signs
Animals were observed daily for morbidity, stool 
consistency and anus appearance. At day 1, TNBS 
group presented an alteration of intestinal motil-
ity characterized by diarrhea or soft stools, severe 
edema of the anus and moderate morbidity. Ethanol 
group showed the same clinical signs, but lightly. At 
day 4 and 7, TNBS group kept the observed clinical 
signs, while in the ethanol group wasn’t identified 
any alteration. Sham group remained without any 
alterations during the study.
Regarding body weight, ethanol and sham 
groups increased the weight of mice during the 
study, but TNBS group showed a decreased body 
weight at day 4 (TABLE 1). 
At day 2, there were 2 deaths in the TNBS group. 
The macroscopic analysis showed a severe obstruc-
tion to the colon filled with large fecal pellets. Se-
vere swelling of the intestinal wall, inflammation 
with presence of generalized strokes. The lesions 
were apparently consistent with toxic megacolon.
Biochemical Marker
ALP was identified in all experimental groups, 
but in different concentrations depending of the 
group was evaluated. TNBS group presented the 
highest values around 32.9 ± 5.5 U/L of serum con-
centration comparing with the other two groups. 
Ethanol and sham groups presented decreased 
values but quite similar around 10.8±1.5 U/L and 
8.5±0 U/L, respectively. 
Assessment of small intestine lesions
The small intestine was analyzed and it showed 
similar histological results among evaluated groups 
and the number of days after induction. Apparently, 
no macroscopic lesions were observed, but 
microscopically, a slight lymphoplasmacytic infiltrate 
in the lamina propria was identified and it was similar 
to all studied groups independently of the day after 
induction (Figure 1).
Assessment of colitis severity
The colon was analyzed and it showed different 
histological results depending of which group was 
evaluated and the number of days after induction. 
Regarding macroscopic evaluation of colon, it 
was observed hemorrhagic focus and edema. 
Microscopically, the TNBS group presented severe 
lesions at day 2 and day 4, whereas no substantial 
Table 1 – Average of body weight during the study.
 TNBS GROUP
 (n=6)
 ETHANOL GROUP
 (n=3)
 SHAM GROUP
 (n=2)
  DAY 0 DAY 4 DAY 7
AVERAGE OF BODY WEIGHT ± SD (g)
 34.3 ± 4.7 29 ± 0 43.3 ± 4.6
 33.6 ± 1.6 44 ± 0 40.5 ± 2.5
 37 ± 2 43 ± 0 47 ± 0
 
Figure 1. Histopathological features of small intestine 
sections (100x) from  (a) TNBS group, (b) Ethanol group, 
(c) Sham group.
"DUB'BSNBDºVUJDB1PSUVHVFTBt7PM/
Development of TNBS-induced colitis: animal model to test new pharmacological approaches     33 
morphological changes were detected at day 7 (Figure 
2). The histopathology analysis revealed severe 
necrosis of the mucosa with widespread necrosis of 
the intestinal glands. The remaining intestinal glands 
were ectasic with squamous metaplasia. Severe 
hemorrhagic and purulent exsudates were observed 
in the submucosa, muscular and serosa.
The assessment of colitis severity was based on 
two main parameters namely (a) epithelial damage 
and (b) infiltration. At day 2 and 4, it was observed 
the higher score (HAI of 8 – severe colitis) for all 
samples evaluated on the TNBS group comparative-
ly to the samples of ethanol and sham group, which 
it was observed no lesions (HAI of 0-unaffected). 
In the ethanol and sham group, no histologi-
cal alterations were observed in the colon (HAI of 0 
– unaffected), independently of the day after induc-
tion (Figure 3).
Discussion
The pathogenesis of IBD is similar between hu-
man disease and TNBS-induced colitis16, and this is 
the reason why so many research groups are now 
using this model to investigate novel approaches for 
the treatment of IBD.
Regarding monitoring of clinical symptoms/
signs, TNBS group presented an alteration of intesti-
nal motility characterized by diarrhea or soft stools, 
severe edema of the anus and moderate morbidity, 
while ethanol and sham groups remained without 
any alterations. These clinical manifestations in the 
TNBS group were expected and compatible with a 
correct induction of UC15,16. The manifestations be-
came maximal at day 4 after induction and resolved 
at day 7. The literature refers that manifestations be-
came maximal from 3 days to 1 week after instilla-
tion, and resolved within 2 weeks8,10-12, depending of 
the dosage of TNBS, the depth of TNBS administra-
tion, and the time point for model evaluation8. The 
peak of clinical symptoms/signs is also confirmed by 
the decreased body weight of TNBS group at day 4, 
comparing with ethanol and sham groups that in-
creased its body weight during the study.  
ALP is regularly measured in clinical practice 
and its changes in serum levels are observed in a 
number of clinical conditions of organs where it 
can be found like bone, liver, bowel and kidney17. 
Therefore, ALP was measured in all experimental 
groups and TNBS group presented the highest val-
ues around 32.9 ± 5.5 U/L of serum concentration 
comparing with ethanol and sham groups (10.8±1.5 
U/L and 8.5±0 U/L, respectively). The low concen-
trations of APL in both control groups (ethanol and 
sham group) suggest that the origin of increased 
APL in the TNBS group is due to intestinal lesion in-
ducted in this study. These our results are consistent 
with other studies, which observed a higher AP ac-
tivity in the colon from colitic animals compared to 
the non-colitic animals from acute intestinal inflam-
mation model induced by TNBS18,19. Intestinal ALP 
has been considered a phenotypic marker of dif-
ferentiation, which is up-regulated in experimental 
chronic diarrhea and IBD19,20. It’s a small intestinal 
Figure 2. Morphologic changes of colon from TNBS 
group in day (a) 2, (b) 4 and (c) 7.
Figure 3. Histopathological features of colon (40x) from 
(a) Ethanol group and (b) Sham group, in day 4 and 7.
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brush-border enzyme that functions as a gut mu-
cosal defense factor, providing resistance to bacte-
rial invasion when the intestine is subject to a certain 
lesion like local or distant ischemic injury21. Based 
on these results, administration of exogenous intes-
tinal ALP enzyme to patients with the active form of 
IBD may be a therapeutic option22.
The histopathological analysis showed a slight 
lymphocytic inflammatory infiltrate in the lamina 
propria similar with all experimental groups. These 
lesions are consistent with a sub-acute to chronic 
process, suggesting no relationship with this study. 
Perhaps, the reason is that mice are not Specific 
Pathogen Free, even because there are similar for 
all experimental groups. These should therefore be 
devalued.
The morphological features of colon in the 
TNBS group were evaluated at day 2, 4 and 7. The 
results revealed severe lesions of tissue between day 
2 and day 4, whereas it was detected no substantial 
morphological changes at day 7. The peak of clini-
cal symptoms/signs is also confirmed by the severe 
lesions at day 4. No histological alterations were ob-
served in the colon from ethanol group and sham 
group. The histopathology analysis revealed severe 
necrosis of the mucosa with widespread necrosis of 
the intestinal glands. The remaining intestinal glands 
were ectasic with squamous metaplasia. Severe 
hemorrhagic and purulent exsudates were observed 
in the submucosa, muscular and serosa. These le-
sions are consistent with a correct induction of UC 
by TNBS15,16.
Conclusion
This study allows concluding that it’s possible 
to develop a TNBS-induced colitis 4 days after 
instillation. This model will be interesting to clarify 
the inflammatory mechanisms associated with 
IBD in order to propose other pharmacological 
modulation of the inflammatory response than the 
currently known, with the main objective to facilitate
a more effective and selective treatment for this 
disease.
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